Prohost Biotech – Exclusive Biotech Research

Exclusive Market Insight

& Scientific analysis

  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Menu
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us

The U.S. FDA Approved Johnson & Johnson AKEEGA™ for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

August 15, 2023 0
Johnson & Johnson’s Janssen Pharmaceutical AKEEGA Johnson & Johnson (JNJ) owned Janssen Pharmaceutical announced that the U.S. FDA has approved AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone for adult patients with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), which no longer responds to androgen deprivation therapy …

The U.S.FDA Granted CellTrans Inc., Approval of its Product Lantidra...

Bayer & BlueRock Therapeutics: A First Neuronal Stem Cell Therapy...

Celmatix Inc: Revolutionizing Fertility Treatments

Intercept Pharmaceuticals Stock is Halted Today as the FDA Advisory...

Longeveron has Encouraging Trial Results for Hypoplastic Left Heart Syndrome

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement...

New Study from Neuvivo’s NP001: First to Link Regulation of...

23andMe Teams Up with Novartis on Lipoprotein(a) Education for its...

As Expected, Seagen Was Taken Over, the Buyer is Pfizer.

XyloCor Therapeutics Reported Positive Safety and Efficacy Results of XC001...

From bluebird bio: FDA Accelerated Approval for SKYSONA® Gene Therapy...

Intellia Therapeutics to Present Data from Clinical Trial of NTLA-2002...

Hutchmed: Treating Advanced Metastatic Colorectal Cancer and Other Treatment Resistant...

Avista Therapeutics Partners with Roche to Develop Advanced AAV Gene...

CytomX Therapeutics Provided an Important Strategic Update

Insilico Medicine: Identifying Multiple Novel Therapeutic Targets for ALS AI-driven...

Vertex Pharmaceuticals and Type 1 Diabetes

An Important Reminder from Vir Biotechnology

Eisai and Biogen: Lecanemab for the Treament of Early Alzheimer’s...

Impacting News

Publication of Two Cases for Treatment of Metastatic Pancreatic Cancer by CARsgen Therapeutics Holdings Limited

September 21, 2023 0
CARsgen Therapeutics Holdings Limited Today, September 21, 2023, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) - …

Alpine Immune Sciences Treating IgA Nephropathy Among Other Diseases

August 31, 2023 0
Alpine Immune Sciences Treating IgA nephropathy Alpine Immune Sciences (ALPN) announced a successful initiation of the …

Exelixis Positive Results in Phase 3 CABINET Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

August 26, 2023 0
Exelixis in the NEWS Exelixis CABOMETYX is approved for the treatment of many cancers. The product …

The Biotechnology Revolution: News from Nuvectis Pharma and Revolution Medicines Publication

August 20, 2023 0
Nuvectis Pharma Nuvectis Pharma (NVCT) is a biopharmaceutical company focused on developing innovative precision targeted drugs …

Xenon Pharmaceuticals Reports 2Q 2023 Financial Results and Provides Corporate Update

August 15, 2023 0
Xenon Pharmaceuticals Q2 Financial Results On  August 09, 2023 , Xenon Pharmaceuticals (XENE) reported financial results for …

TG Therapeutics Will Have An Important Conference Call at 8:30 AM Tomorrow, August 1st

July 31, 2023 0
TG Therapeutics Conference Call TG Therapeutics (TGTX) announced that, tomorrow, Tuesday, August 1, 2023, a conference …

Trick or Trade

Our Eyes Are on Reata Pharmaceuticals Today

May 25, 2023 0
Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals (RETA) announced a setback of its chronic kidney disease …

Why the Current Interest in Ventyx Biosciences

March 7, 2023 0
The Current Interest in Ventyx Biosciences Answered 1. Ventyx Biosciences Focus  We like the fact that Ventyx …

Endogena Therapeutics: Treating Retinitis Pigmentosa and Other Devastating Degenerative Diseases

February 8, 2023 0
Endogena Therapeutics The US FDA designated Fast Track development program for the investigation of Endogena Therapeutics' …

Xenon Pharmaceuticals: A Newly Selected Clinical-Stage Firm. See Also: Recently Selected Clinical Stage Firms

February 7, 2023 0
Xenon Pharmaceuticals Xenon Pharmaceuticals (XENE) - a clinical stage biopharmaceutical company developing novel  treatments aimed at improving …

Could We Soon Have a Specific Treatment for the Rare Disease IgA Nephritis?

February 2, 2023 0
It's Time to Remind About Travere Therapeutics The time has come to remind that the U.S. …
Stocks Outperforming Today

Stocks Outperforming Today

January 5, 2023 0
January 5, 2023 In Today's Down Market the stocks that are outperforming are as follows: Reata …

Today’s Highlights

Reata Stock Holders Approved the Firm’s Merger with Biogen

September 21, 2023 0
Reat Pharmaceuticals Merger with Biogen Reata Pharmaceuticals announced that at a special meeting held today, preliminary …

Orchard Therapeutics: FDA Acceptance of BLA Application for Product OTL-200 for the Treatment of Metachromatic Leukodystrophy

September 18, 2023 0
Orchard Therapeutics in the NEWS Today, September 18, 2023, Orchard Therapeutics (ORTX) - a global gene …

Neurocrine Biosciences: Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia

September 12, 2023 0
Neurocrine Biosciences in the NEWS Today, Neurocrine Biosciences (NBIX) announced positive top-line data from Phase 3 …

Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly 

September 11, 2023 0
Crinetics Pharmaceuticals Once Daily, Oral Treatment for Acromegaly Crinetics Pharmaceuticals (CRNX) announced that its oral and …

Halozyme Therapeutics ENHANZE Reduces Roche’s Tecentriq® Treatment Time to 7 Minutes from 30-60

August 29, 2023 0
Halozyme Therapeutics in the NEWS Halozyme Therapeutics (HALO) announced today that the Medicines and Healthcare Products …

Arcus Biosciences Participates in Multiple Upcoming Investor Conferences. The Stock is Boosted. See Also: Today’s Roche Press Release

August 23, 2023 0
Arcus Biosciences Arcus Biosciences (RCUS) is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination …

Latest Articlesddd

Reata Stock Holders Approved the Firm’s Merger with Biogen

September 21, 2023 0
Reat Pharmaceuticals Merger with Biogen Reata Pharmaceuticals announced that at a special meeting held today, preliminary …

Publication of Two Cases for Treatment of Metastatic Pancreatic Cancer by CARsgen Therapeutics Holdings Limited

September 21, 2023 0
CARsgen Therapeutics Holdings Limited Today, September 21, 2023, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) - …

Orchard Therapeutics: FDA Acceptance of BLA Application for Product OTL-200 for the Treatment of Metachromatic Leukodystrophy

September 18, 2023 0
Orchard Therapeutics in the NEWS Today, September 18, 2023, Orchard Therapeutics (ORTX) - a global gene …

Discovering The Root Causes of Diseases

September 15, 2023 0
Prohost Letter #457 Discovering The Root Causes of Diseases   Biotech firms with solid scientific fundamentals …

Neurocrine Biosciences: Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia

September 12, 2023 0
Neurocrine Biosciences in the NEWS Today, Neurocrine Biosciences (NBIX) announced positive top-line data from Phase 3 …

Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly 

September 11, 2023 0
Crinetics Pharmaceuticals Once Daily, Oral Treatment for Acromegaly Crinetics Pharmaceuticals (CRNX) announced that its oral and …

Alpine Immune Sciences Treating IgA Nephropathy Among Other Diseases

August 31, 2023 0
Alpine Immune Sciences Treating IgA nephropathy Alpine Immune Sciences (ALPN) announced a successful initiation of the …

Halozyme Therapeutics ENHANZE Reduces Roche’s Tecentriq® Treatment Time to 7 Minutes from 30-60

August 29, 2023 0
Halozyme Therapeutics in the NEWS Halozyme Therapeutics (HALO) announced today that the Medicines and Healthcare Products …

Exelixis Positive Results in Phase 3 CABINET Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

August 26, 2023 0
Exelixis in the NEWS Exelixis CABOMETYX is approved for the treatment of many cancers. The product …

Arcus Biosciences Participates in Multiple Upcoming Investor Conferences. The Stock is Boosted. See Also: Today’s Roche Press Release

August 23, 2023 0
Arcus Biosciences Arcus Biosciences (RCUS) is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination …

Regeneron Pharmaceuticals EYLEA HD Approved by FDA for Wet Age-related Macular Degeneration, Diabetic Macular Edema and Diabetic Retinopathy

August 21, 2023 0
Regeneron Pharmaceuticals EYLEA HD Approved by the FDA Regeneron Pharmaceuticals (REGN) announced that the U.S. FDA has …

The Biotechnology Revolution: News from Nuvectis Pharma and Revolution Medicines Publication

August 20, 2023 0
Nuvectis Pharma Nuvectis Pharma (NVCT) is a biopharmaceutical company focused on developing innovative precision targeted drugs …

The U.S. FDA Approved Johnson & Johnson AKEEGA™ for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

August 15, 2023 0
Johnson & Johnson’s Janssen Pharmaceutical AKEEGA Johnson & Johnson (JNJ) owned Janssen Pharmaceutical announced that the U.S. …

Xenon Pharmaceuticals Reports 2Q 2023 Financial Results and Provides Corporate Update

August 15, 2023 0
Xenon Pharmaceuticals Q2 Financial Results On  August 09, 2023 , Xenon Pharmaceuticals (XENE) reported financial results for …

Reminders About CymaBay Therapeutics and Jazz Pharmaceuticals Conference Calls Today at 4.30 PM

August 10, 2023 0
CymaBay Therapeutics and Jazz Pharmaceuticals Conference Call Info CymaBay Therapeutics: Hosting a Conference Call and Live …

TG Therapeutics Will Have An Important Conference Call at 8:30 AM Tomorrow, August 1st

July 31, 2023 0
TG Therapeutics Conference Call TG Therapeutics (TGTX) announced that, tomorrow, Tuesday, August 1, 2023, a conference …

ImmunoGen Reports Recent Progress and 2Q 2023 Financial Results. In Other News, Anna Berkenblit, MD, Senior VP and CMO Stepping Down from Her Position

July 31, 2023 0
ImmunoGen in the News WALTHAM, Mass.--(BUSINESS WIRE) --Jul. 31, 2023-- ImmunoGen (IMGN), a leader in the …

Merck and Moderna Initiated Phase 3 Study Evaluating V940 in Combination with KEYTRUDA® for Patients with Resected High-Risk Melanoma

July 26, 2023 0
Merck and Moderna Inc Announcement Merck (MRK) and Moderna Inc (MRNA . . . This content …

Why Syndax and Incyte Traded UP in Today’s Early Morning  

July 24, 2023 0
Syndax Pharmaceuticals and Incyte Syndax Pharmaceuticals (SNDX) and Incyte (INCY) announced positive data from the pivotal …

Halozyme Therapeutics’ Positive Results for Patients with Chronic Inflammatory Demyelinating Polyneuropathy

July 21, 2023 0
The way drugs are being delivered into patients’ bodies have become more than ever considered important …

Posts navigation

1 2 3 4 … 64 Next

Prohost Letters

Discovering The Root Causes of Diseases

September 15, 2023 0
Prohost Letter #457 Discovering The Root Causes of Diseases   Biotech firms with solid scientific fundamentals …

Treatments for Untreatable Diseases

July 16, 2023 0
Prohost Letter #456 Treatments for Untreatable Diseases The revolution in biotechnology is not meant to offer …
Prohost Letter #455

Prohost Letter #455

June 28, 2023 0
Prohost Letter #455 Introduction Our Prohost Letter disappeared for six months. Several reasons dictated our decision …

Gilead Sciences – Still Way Undervalued

December 29, 2022 0
Prohost Letter #453 Gilead Sciences Still Way UNDERVALUED Finally, many analysts who happened to downgrade Gilead …

Treating Untreatable Disease – NASH

October 13, 2022 0
Prohost Letter #452 Treating Untreatable Disease - NASH Non Alcoholic Steatohepatitis  The efforts spent on treating …

Shorting Biotech Firms with Solid Fundamentals

July 19, 2022 0
Prohost Comprehensive Letter #451 Shorting Biotech Firms with Solid Fundamentals Unfair shorting of promising stocks seems …

Search ProhostBiotech

Popular Links

Aerie Pharmaceuticals (AERI) Agenus (AGEN) Alnylam Pharmaceuticals (ALNY) Amgen (AMGN) Array BioPharma (ARRY) AstraZeneca Plc (AZN) Bellicum Pharmaceuticals Inc (BLCM) Bristol-Myers Squibb (BMY) Celgene (CELG) Celldex Therapeutics (CLDX) Cellectis (CLLS) Celyad (CYAD) Compugen (CGEN) CRISPR Therapeutics (CRSP) CytomX Therapeutics Inc (CTMX) Editas Medicine Inc (EDIT) Enanta Pharmaceuticals (ENTA) Exelixis (EXEL) Gilead Sciences (GILD) Halozyme Therapeutics (HALO) Illumina (ILMN) ImmunoGen (IMGN) Incyte (INCY) Innoviva (INVA) Intellia Therapeutics (NTLA) Ionis Pharmaceuticals Inc (IONS) Karyopharm Therapeutics Inc (KPTI) Merck (MRK) Moderna Inc (MRNA) Nektar Therapeutics (NKTR) Novartis (NVS) Portola Pharmaceuticals Inc (PTLA) PTC Therapeutics (PTCT) Regeneron Pharmaceuticals (REGN) Regenxbio (RGNX) Rhythm Pharmaceuticals Inc (RYTM) Sangamo Therapeutics Inc (SGMO) Sarepta Therapeutics (SRPT) Seagen Inc (SGEN) Spark Therapeutics Theravance Biopharma (TBPH) Vertex Pharmaceuticals (VRTX) Xoma (XOMA)
  • Recent

ProhostBiotech Archive

Sign Up for Weekly Emails

Prohost Biotech – Exclusive Biotech Research Copyright © 2023.
© 2014 Prohost Biotech. All rights reserved.

Privacy Policy | Cancellation Policy | Forward Looking Statement